1. English
  2. English

EmmaCOPD

600.000 people in the Netherlands have COPD. Because of lung attacks (exacerbations) 30.000 of them spend 200.000 days in hospital yearly, a societal cost of € 150 million. EmmaCOPD, a COPD lung attack recognition and rehabilitation application on top of the Emma platform prevents most hospital readmissions. The application may currently be amongst the most effective solutions to reduce the number of days COPD patients spend in hospital (avg. hospital stay reduction in test group above 80%). The application was developed with the help of Bravis Hospitals in Bergen op Zoom and Roosendaal and has been validated since April 2018 by the team of Prof. Niels Chavannes of Leiden University Medical Center.
Background
Geographical scope: 
National level
Region involved:
Countries involved:
Organisation
Organisation name: 
Medicine Men BV
Organisation address: 
Hollandse kade 27-B Abcoude The Netherlands...
Kind of organisation: 
Private companies
Small-sized industry
Viability
Time for deployment: 
Less than a year
Preparation of implementation: 
- selected for EU subsidy to support product development - found hospital to do agile development with patients and care givers - found University Medical Centre to do validation research - did validation study during 20 months with new group to proove concept and effectiveness item local tv...
Investment per citizen / service user / patient: 
Between 100 – 1.000 EUR per targeted citizen / patient
Cost calculation: 
- Platform development cost based on 20.000 development hours will not be retrieved in the short term. - Smartwatch used purchasing cost around 200 euro - Savings within target COPD patient group around 10 days per year (€ 3.500-€ 7.000 per year) - we charge 15%-25% of savings (results based) ...
Evidence of practice: 
Agreed evidence. Evidence is based on an agreed established monitoring system/process before and after implementation of the good practice
Evidence creation: 
Leiden University Medical Centre performed research between april 2018 and december 2019 (20 months) on group of 30 COPD Gold 3/4 patients under supervision by lung physicians at Bravis Hospital in The Netherlands. The prospecive study used the Electronic Health Records of the test group to compare...
Maturity level: 
There is evidence that the practice is economically viable and brings benefits to the target group. Further research and development is needed in order to achieve market impact and for the practice to become routine use
Maturity level detalis: 
The practice is proven to be effective. We are in discussion with the largest Dutch health insurers to define the optimal business model and inclusion criteria for the practice. We expect the practice to be widely available on the Dutch market before summer 2020.
Time of impact: 
Long term and sustainable impact – e.g. a long time after the pilot project ended and routine day-to-day operation began
Kind of impact: 
Less hospital re-admission (economic)
Aspects time of impact: 
Patients all reported beter quality of life and less isolation. The Emma platform allows ALL informal and professional carers in ANY care organisation to communicate with the patient and to view all sensory and health parameters. EmmaCOPD reuced hospital admissions and shortens hospital stay...
Transferability level: 
The innovative practice has been transferred within the same country.
Transferability details: 
We are preparing the first new installations of EmmaCOPD in other Dutch regions. Through the EIT Go Global program in 2019 we have selected other EU countries to transfer the practice to by the end of 2020.
Initiative
Type of Practice: 
Notable practice
Stakeholders concerned: 
Hospitals
Primary care centres
Specialised physicians
General practioners
Nurses
Home care centres
Informal caregivers
Private companies
Research centres
Academia
National public authorities , WHO
Reach of initiative: 
100 - 249
Age group: 
50 - 64
65 - 79
80+
Baseline information: 
COPD patients often experience lung exacerbations. Patients are being hospitalized when the exacerbation is of a serious nature. Depending on the patient status the length of stay is between 5 and 20 days. In the Netherlands hospitals cost is € 150 million per year. Current practice is for...
Source of funding: 
Private funding